Clinical Research Directory
Browse clinical research sites, groups, and studies.
Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Monitoring Circulating Tumor DNA
Sponsor: University Hospital, Rouen
Summary
The goal of the REMNANT study is to confirm the clinical value of detecting a new biomarker, ctDNA (circulating tumor DNA), in the follow-up of patients with operated liver cancer. In order to meet this objective, this biomarker will be measured in your blood before and after surgery, at three and six months.
Official title: Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Monitoring Circulating Tumor DNA: a Prospective Cohort Study
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
150
Start Date
2022-08-04
Completion Date
2029-02
Last Updated
2026-02-06
Healthy Volunteers
No
Conditions
Interventions
circulating tumor DNA dosage
blood sample for circulating tumor DNA dosage will be done to patient with hepatocellular carcinoma
Locations (1)
Chu Rouen
Rouen, France